Reducing CV risk in diabetes: An ADA update.

Skolnik N, Jaffa FM, Kalyani RR, Johnson E, Shubrook JH. Reducing CV risk in diabetes: An ADA update. J Fam Pract. 2017 May; 66(5):300-308.

View in: PubMed

subject areas

Antihypertensive Agents
Aspirin
Benzhydryl Compounds
Cardiovascular Diseases
Contraindications
Creatinine
Diabetes Complications
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Dose-Response Relationship, Drug
Drug Chronotherapy
Ezetimibe
Fenofibrate
Glucosides
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias
Hypertension
Hypoglycemic Agents
Hypolipidemic Agents
Life Style
Liraglutide
Metformin
Niacin
Platelet Aggregation Inhibitors
Proprotein Convertase 9
Risk Reduction Behavior
Thiazolidinediones

authors with profiles

Neil Skolnik

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement